✦ LIBER ✦

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

✍ Scribed by Shinya Arinaga; Nobuya Karimine; Kiyoshi Takamuku; Shigeru Nanbara; Hiroshi Inoue; Ryoji Abe; Daisuke Watanabe; Hideo Matsuoka; Hiroaki Ueo; Tsuyoshi Akiyoshi

Publisher: Springer-Verlag
Year: 1992
Tongue: English
Weight: 534 KB
Volume: 35
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01789330

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cytotoxic cell function and phenotypic a

Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C

✍ Shinya Arinaga; Nobuya Karimine; Masashi Adachi; Hiroshi Inoue; Shigeru Nanbara; 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 758 KB

Long-term immunotherapy with low-dose in

Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma

✍ Carlo Buzio; Simeone Andrulli; Rosaria Santi; Laura Pavone; Rodolfo Passalacqua; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Intensive recombinant interleukin-2 and

Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma

✍ Susan G. Urba; Arlene A. Forastiere; Gregory T. Wolf; Philip C. Amrein 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB

Lack of correlation between peripheral b

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t

Interleukin-2 dose, blood monocyte and C

Interleukin-2 dose, blood monocyte and CD25+lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

✍ Gregers G. Hermann; Poul F. Geertsen; Hans von der Maase; Jesper Zeuthen 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 583 KB

Chemo-immunotherapy in patients with met

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with decarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response

✍ Rut Isacson; Eli Kedar; Vivian Barak; Zulma Gazit; Oded Yurim; Inna Kalichman; H 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 576 KB